CTIS2023-509761-21-00招募中1 期
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers - 2023/805
Centre Hospitalier Regional Universitaire0 个研究点目标入组 174 人开始时间: 2023年12月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11, oxaliplatin, anti-VEGF, trifluridine/tipiracil, and anti-EGFR therapy if KRAS and NRAS WT, anti-BRAF therapy if BRAF V600E mutated, and anti-PD1 if MSI-H/dMMR tumor), or not considered as candidate for these treatments., No contraindication to Iodine contrast media injection during CT, For female patients of childbearing potential, negative pregnancy test within 14 days before starting the study drug. Men and women are required to use adequate birth control during the study (when applicable),, Signed and dated informed consent,, Ability to comply with the study protocol, in the Investigator’s judgment., Registration in a national health care system (CMU included)., Life expectancy of at least 3 months, Female or male with age >18 years old, Performance status = 0 or 1 (Annex 1), Measurable disease defined according to RECIST v1.1 guidelines (scanner or MRI) (Annex 2), Adequate bone marrow, liver and renal functions: Haemoglobin = 9 g/dL; absolute neutrophil count (ANC) = 1.5 x 109/L; platelets = 100 x 109/L, Total serum bilirubin = 1.5 times upper normal value (ULN), serum alkaline phosphatase < 5 times ULN, aminotransferases (AST/ALT) = 3 × ULN in absence of hepatic metastasis or = 5 if presence of hepatic lesions, Cockcroft glomerular filtration rate > 50 ml/min, Proteinuria <2+ (dipstick urinalysis) or =1g/24hour
排除标准
- •Diagnosis of additional malignancy within 2 years prior to the inclusion (exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical and/or bladder cancer),, 10.Known hypersensitivity to any of the study drugs, study drug classes or excipient in the formulation: -History of severe and unexpected reactions to fluoropyrimidine therapy, -History of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory medicines, -Mastocytosis, for whom the use of acetylsalicylic acid can cause severe hypersensitivity reactions,, 11.Unresolved toxicity higher than CTCAE (v5) Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neuropathy = Grade 2,, 12.Subject unable to swallow oral medications or any malabsorption condition,, 13.Inadequate organ functions: -known cardiac failure of unstable coronaropathy, respiratory failure, or uncontrolled infection or another life-risk condition -Congestive Heart Failure = New York Heart Association (NYHA) class 2, -Myocardal infarction less than 6 months before start of study drug, unstable angina (anginal symptoms at rest), new-onset angina (begun within the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted), -Uncontrolled hypertension (defined by systolic blood pressure = 150 mmHg and/or diastolic pressure = 100 mmHg despite optimal medical management), or history of hypertensive crisis, or hypertensive encephalopathy -Pleural effusion or ascites that causes respiratory compromise (= CTCAE grade 2 dyspnea), -Interstitial lung disease with ongoing signs or symptoms, -Ongoing infection >grade 2 CTCAE V5, -Dehydration CTCAE v5 grade =1, -Urinary tract obstruction, 14.Constitutional or acquired hemorrhagic disease: -Any haemorrhage or bleeding event = CTCAE Grade 3 within 4 weeks prior to the start of study medication, -History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to inclusion, -Serious, Non-healing wound, active peptic ulcer or untreated bone fracture, -Major surgical procedure, open biopsy or significant traumatic injury within 28 days before start of study medication,, 15.Planned surgical procedure within the first month of treatment or any procedure that might change the timing of regorafenib administration during the first month of treatment,, 16.Known History of human immunodeficiency virus (HIV) infection; Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy,, 17.Receipt of yellow fever vaccine within 28 days prior to study,, 18.History of organ allograft,, 19.Pregnant or breast-feeding subjects, 2.Current participation in a study of an investigational agent or in the period of exclusion, 3.Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion in the trial ;, 4.Patient under judicial protection (curatorship, tutorship) and/or deprived of freedom,, 5.Previous exposition to regorafenib or anti-angiogenic treatment other than bevacizumab and aflibercept, 6.Treatment with any other investigational medicinal product within 28 days prior to study entry, EXCEPT for ASPIRIN,, 7.Sy
研究者
相似试验
进行中（未招募）
1 期
_advanced Biliary Tract CancerMedDRA version: 17.0Level: PTClassification code 10055111Term: Biliary cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004385-34-FRInstitut régional du Cancer - Montpellier - Val d'Aurelle87
招募中
1 期
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma - REGO-INTER-EWING1ewly diagnosed patients with metastatic (other than lung/pleura metastases only) Ewing sarcomaCTIS2023-503322-39-00Institut Gustave Roussy29
进行中（未招募）
1 期
Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinomaAn open-label phase IIMetastatic colorectal cancerEUCTR2020-002344-23-FRCHU de Besançon49
进行中（未招募）
1 期
Regorafenib followed by Nivolumab in patients with Hepatocellular Carcinoma progressing under sorafenibMedDRA version: 20.0 Level: PT Classification code 10073071 Term: Hepatocellular carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Hepatocellular carcinomaEUCTR2019-003108-10-ESFundació Clinic per a la Recerca Biomèdica60
进行中（未招募）
1 期
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.Patient with metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10010028Term: Colorectal cancer Duke's DSystem Organ Class: 100000004864EUCTR2016-002222-37-DKHerlev og Gentofte Hospital60